Rare Disease Legislative Advocates

Rare Disease Legislative Advocates
Name	Rare Disease Legislative Advocates
Type	Advocacy organization
Focus	Rare disease policy, patient advocacy, legislative affairs
Founded	2013
Headquarters	Washington, D.C.
Parent organization	National Organization for Rare Disorders

Rare Disease Legislative Advocates is an advocacy program focused on coordinating rare disease patient organizations and stakeholders to influence policy in the United States and internationally. It operates as a legislative arm connecting patient advocates with lawmakers, policymakers, industry representatives, and academic experts. The program organizes events, briefings, and campaigns to advance legislation, research funding, and regulatory pathways for orphan drugs and rare condition services.

Background and Mission

Rare Disease Legislative Advocates was established to amplify voices from patient groups such as National Organization for Rare Disorders, Cystic Fibrosis Foundation, Muscular Dystrophy Association, Global Genes, and EveryLife Foundation for Rare Diseases by engaging legislative bodies including the United States Congress, European Parliament, United States Senate, United States House of Representatives, and state legislatures. Its mission aligns with milestones like the Orphan Drug Act and initiatives by agencies such as the Food and Drug Administration, National Institutes of Health, Centers for Disease Control and Prevention, and the European Medicines Agency. Founders and advisors have engaged figures and institutions including Senator Orrin Hatch, Representative Greg Walden, Barack Obama, Donald Trump, Joe Biden, Bill Clinton, George W. Bush, Hillary Clinton, and influencers from Harvard University, Johns Hopkins University, Stanford University, Massachusetts Institute of Technology, and Yale University to frame legislative strategies.

Advocacy Activities and Programs

The organization coordinates annual activities such as lobby days, briefings, and advocacy training with partners like Patient-Centered Outcomes Research Institute, Biotechnology Innovation Organization, PhRMA, American Medical Association, and Rare Disease UK. It organizes meetings with committees like the House Energy and Commerce Committee, Senate Health, Education, Labor and Pensions Committee, House Appropriations Committee, and engages officials from Office of Management and Budget, Department of Health and Human Services, Centers for Medicare & Medicaid Services, and United States Agency for International Development on cross-cutting issues. Educational programs bring together researchers and advocates affiliated with National Cancer Institute, National Institute of Neurological Disorders and Stroke, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Wellcome Trust, and academic centers such as Mayo Clinic, Cleveland Clinic, UCLA Health, and Mount Sinai Health System.

Legislative Impact and Policy Priorities

Policy priorities include securing appropriations for National Institutes of Health programs, improving regulatory pathways at the Food and Drug Administration, expanding access via Medicare and Medicaid, and refining intellectual property and incentive structures such as those shaped by the Bayh-Dole Act and the Biologics Price Competition and Innovation Act. The program has supported legislative measures and hearings featuring lawmakers like Senator Elizabeth Warren, Senator Chuck Grassley, Representative Anna Eshoo, Representative Rosa DeLauro, Senator Patty Murray, Senator Lindsey Graham, Representative Kevin McCarthy, and Senate Majority Leader figures across sessions. It tracks international policy trends involving European Medicines Agency, World Health Organization, Organisation for Economic Co-operation and Development, G7, and G20 health commitments.

Organizational Structure and Funding

Structured as a program under National Organization for Rare Disorders, governance includes advisory input from boards and committees with leaders drawn from patient advocacy groups such as Alpha-1 Foundation, Huntington's Disease Society of America, Spinal Muscular Atrophy Foundation, Amyloidosis Foundation, and Alliance for Lupus Research. Funding sources include philanthropic gifts from foundations like Bill & Melinda Gates Foundation, The Rockefeller Foundation, and corporate sponsorship from biotechnology and pharmaceutical companies represented by Genentech, Amgen, Pfizer, Novartis, Roche, Sanofi, Eli Lilly and Company, Johnson & Johnson, AstraZeneca, and GlaxoSmithKline. Grantmaking collaborations involve entities such as Robert Wood Johnson Foundation, The Wellcome Trust, and patient-focused funders including Chan Zuckerberg Initiative.

Partnerships and Coalitions

The program collaborates with coalitions and organizations including Global Commission on Drug Policy, Rare Diseases International, EURORDIS, European Organisation for Rare Diseases, International Rare Diseases Research Consortium, Coalition for Accessible Treatments, AllTrials, Access to Medicine Foundation, Council for Responsible Nutrition, and academic consortia at Imperial College London, University College London, Karolinska Institutet, McGill University, and University of Toronto. It partners with advocacy and policy groups such as AARP, American Association for the Advancement of Science, The Lancet, New England Journal of Medicine, Science (journal), Nature (journal), and media platforms that amplify patient stories including CNN, The New York Times, The Washington Post, BBC News, and NPR.

Notable Campaigns and Outcomes

Notable campaigns have targeted expansion of newborn screening policies in coordination with state public health departments and organizations like March of Dimes and have supported legislation that interacts with the 21st Century Cures Act, RACE for Children Act, and appropriations for the National Center for Advancing Translational Sciences. Outcomes include increased congressional briefings, testimony involving experts from National Academies of Sciences, Engineering, and Medicine, successful advocacy for funding lines within NIH institutes, and contributions to policy dialogues around pricing and access debated by lawmakers including Senator Bernie Sanders and Senator Bill Cassidy. The program’s campaigns have catalyzed collaborations among stakeholders from industry, academia, patient groups, and global health bodies to advance diagnostics, clinical trial networks, and rare disease registries.

Category:Patient advocacy Category:Health policy